Annapolis, Md.-based Vision Innovation Partners is combating the COVID-19 pandemic by suspending all nonemergency appointments and elective surgeries throughout its network of affiliated practices, effective March 16.
Ophthalmology
No private equity firms entered the ophthalmology space in the fourth quarter of 2019, making it the first time in about two years that the market had no new entrants, according to Physicians First's 2020 ophthalmology outlook report.
Ophthalmology-focused pharmaceutical compounding business ImprimisRx has entered into a product supply agreement with iOR Partners.
Boise, Idaho-based Hollingshead Eye Center installed the WaveLight Refractive Suite for Lasik surgery.
EyePoint Pharmaceuticals reported $8.6 million and $20.4 million in fourth-quarter and 2019 revenues, respectively.
Advertisement
COVID-19 poses little risk to ophthalmology and its patients, despite the high global and national public health threat, the Ophthalmology Times reports.
Three recent ophthalmic ASC and practice acquisitions:
Opthalmologists feel like they are spending too much time with paperwork and experiencing EHR burnout like other physicians, yet they maintain a lower level of burnout compared to other physicians, according to Medscape's 2020 ophthalmologist lifestyle, happiness and burnout report.
The Vision Center Network of America is the first and only clinically integrated network for ophthalmic ASCs, according to the Ophthalmic ASC magazine.
Annapolis, Md.-based Vision Innovation Partners went through an identity crisis before establishing its current moniker, but the growing mid-Atlantic private equity platform is establishing a stronghold in the region with no plans of stopping.